Agios Pharmaceuticals (NASDAQ:AGIO) Rating Reiterated by Cowen

Cowen restated their buy rating on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a research report sent to investors on Thursday morning, TipRanks reports.

Other equities analysts also recently issued reports about the stock. Oppenheimer reissued a hold rating on shares of Agios Pharmaceuticals in a report on Thursday. Piper Jaffray Companies cut their price target on shares of Agios Pharmaceuticals from $80.00 to $70.00 and set an overweight rating on the stock in a report on Monday, October 28th. Needham & Company LLC reissued a buy rating and issued a $71.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, October 31st. BidaskClub raised shares of Agios Pharmaceuticals from a hold rating to a buy rating in a report on Monday, January 20th. Finally, ValuEngine downgraded shares of Agios Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, January 29th. One research analyst has rated the stock with a sell rating, three have given a hold rating and ten have given a buy rating to the company’s stock. Agios Pharmaceuticals presently has a consensus rating of Buy and an average price target of $62.10.

NASDAQ AGIO opened at $51.51 on Thursday. Agios Pharmaceuticals has a 1 year low of $28.36 and a 1 year high of $68.94. The company has a fifty day moving average price of $49.93 and a 200-day moving average price of $41.17.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.60) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.72) by $0.12. The company had revenue of $35.44 million during the quarter, compared to analysts’ expectations of $33.72 million. Agios Pharmaceuticals’s quarterly revenue was up 18.1% compared to the same quarter last year. During the same period last year, the firm posted ($1.58) earnings per share. Analysts forecast that Agios Pharmaceuticals will post -6.35 earnings per share for the current fiscal year.

In other Agios Pharmaceuticals news, insider Christopher Bowden sold 49,638 shares of the company’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $50.08, for a total transaction of $2,485,871.04. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Carman Alenson sold 2,950 shares of the company’s stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $50.09, for a total transaction of $147,765.50. The disclosure for this sale can be found here. 3.16% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Advisory Services Network LLC lifted its holdings in Agios Pharmaceuticals by 1,150.0% during the fourth quarter. Advisory Services Network LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 920 shares during the last quarter. Steward Partners Investment Advisory LLC lifted its holdings in Agios Pharmaceuticals by 430.6% during the third quarter. Steward Partners Investment Advisory LLC now owns 1,109 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 900 shares during the last quarter. Advisor Group Inc. lifted its holdings in Agios Pharmaceuticals by 551.3% during the fourth quarter. Advisor Group Inc. now owns 1,244 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 1,053 shares during the last quarter. First Mercantile Trust Co. purchased a new stake in Agios Pharmaceuticals during the third quarter valued at about $44,000. Finally, US Bancorp DE lifted its holdings in Agios Pharmaceuticals by 146.5% during the fourth quarter. US Bancorp DE now owns 1,427 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 848 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.

Further Reading: What are the qualifications of a portfolio manager?

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.